Poxel (OTCMKTS:PXXLF) Cut to Strong Sell at ValuEngine

Poxel (OTCMKTS:PXXLF) was downgraded by stock analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a note issued to investors on Tuesday, ValuEngine reports.

Shares of OTCMKTS PXXLF traded up $0.21 during trading on Tuesday, reaching $9.24. 500 shares of the stock traded hands, compared to its average volume of 1,996. Poxel has a 52-week low of $5.85 and a 52-week high of $9.70. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.80 and a quick ratio of 1.80. The company has a 50-day moving average of $7.00 and a 200-day moving average of $7.84. The stock has a market capitalization of $226.93 million, a P/E ratio of 14.67 and a beta of 0.24.

Poxel Company Profile

Poxel SA, a biopharmaceutical company, develops drugs for metabolic diseases with a primary focus on type II diabetes. Its lead product is Imeglimin, an oral anti-diabetic candidate, which is in Phase III clinical development stage that targets the organs of diabetes, such as pancreas, liver, and muscles.

Further Reading: How interest rates affect municipal bond prices

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Poxel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poxel and related companies with MarketBeat.com's FREE daily email newsletter.